Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, December 10 2021 - 22:35
AsiaNet
Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition
TEL AVIV, Israel, December 10, 2021 /PRNewswire-AsiaNet/--

MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart 
Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and 
$200,000 Award

Donisi Health [https://donisihealth.com/](Donisi) prevailed in this year’s ICI 
Innovation Competition – the premier international conference for innovations 
in cardiovascular intervention.  Competing against startups from all over the 
world in front of a panel of twenty industry expert judges, Donisi took home 
First Place honors and a $200,000 award for their innovative solution to enable 
in-home monitoring for key health bio-markers for patients with Congestive 
Heart Failure (CHF) and other chronic diseases. 

Donisi has the only clinically validated, contact-free technology that can 
detect signs of pulmonary congestion remotely, supporting the continuum of care 
for remote patient monitoring and hospital-at-home services.  Based upon 
FDA-cleared technology and backed by 11 granted patents, Donisi’s AI-based 
system detects and analyzes multiple health bio-indicators simultaneously - 
without the need to remove clothing or connect the patient to wires or patches 
- delivering clinically meaningful insights and notifications of changes in key 
health indicators. 

“We are honored to be recognized  by this prestigious institution, and are 
grateful to the ICI team for highlighting our breakthrough technology’s 
potential to meaningfully improve cardiovascular health,” said Donisi’s CEO 
Yair Brosh.  “We are focused on developing solutions for chronic patients at 
home, with a goal to reduce readmission rates for CHF patients..”

In the United States, CHF is the #1 cause of readmission among Medicare (65+) 
patients, with at least 20% of patients readmitted within 30 days and 50% 
within 6 months.  With an average cost of readmissions in the tens of thousands 
of dollars per patient, direct medical costs for CHF in the US total over $21.7 
billion annually. 

”This doesn’t need to be the case,” said Donisi’s new Chief Medical Officer, 
Dr. Shaddy Hassan. “It is known that when heart failure exacerbations are 
detected early, and healthcare teams intervene while patients are still at home 
before their condition worsens, many of these costly readmissions can be 
avoided, resulting in significant cost reduction and improved quality of life.”

This award marks the latest in a highly successful year for the HealthTech 
Startup beginning with a $1M BIRD grant [ 
https://www.calcalistech.com/ctech/articles/0,7340,L-3888593,00.html?fbclid=IwAR1ids7FCSMPmZes-KkuPHgNfinKUM34uLPvgwjEJQqyYJ2PX8T4Y6S_e9w] 
awarded in partnership with Dell Technologies in January, scientific article 
publication [ 
https://www.tandfonline.com/doi/abs/10.1080/03091902.2021.1905896?journalCode=ijmt20], 
a de novo FDA clearance and First Place at MEDinISRAEL 
[https://vimeo.com/535866905] in April, and Future Unicorn award by E&T 
Magazine [ 
https://finance.yahoo.com/news/donisi-health-named-2021s-future-105300198.html?.tsrc=fin-srch], 
among others.

For more information please contact:
Hannah Carimi
Donisi Health, Israel
hannah.carimi@donisihealth.com

Michael Seggev
Donisi Health, US
michael.seggev@donisihealth.com

Photo - https://mma.prnewswire.com/media/1705485/Donisi_Health_Wins_ICI.jpg 

Source: ContinUse Biometrics, dba Donisi Health, Donis
Translations

Japanese